Guangzhou Bibete Pharmaceutical Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
160
- Stock Symbol
-
688759
- Share Price
-
$2.43
- (As of Friday Closing)
Guangzhou Bibete Pharmaceutical General Information
Description
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
Contact Information
Website
www.bebettermed.cnCorporate Office
- Number 25, Yayingshi Road
- Huangpu District
- Guangzhou, Guangdong 510663
- China
Corporate Office
- Number 25, Yayingshi Road
- Huangpu District
- Guangzhou, Guangdong 510663
- China
Guangzhou Bibete Pharmaceutical Stock Performance
As of 13-Nov-2026, Guangzhou Bibete Pharmaceutical’s stock price is $2.43. Its current market cap is $1.09B with 450M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.43 | $2.46 | $2.15 - $8.24 | $1.09B | 450M | 5.04M | -$0.06 |
Guangzhou Bibete Pharmaceutical Financials Summary
As of 30-Sep-2026, Guangzhou Bibete Pharmaceutical has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,235,589 | 1,852,281 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (29,123) | (19,905) | (7,038) | (24,083) |
| Net Income | (28,672) | (21,417) | (7,804) | (24,418) |
| Total Assets | 240,775 | 245,329 | 45,544 | 62,336 |
| Total Debt | 465 | 628 | 800 | 858 |
Guangzhou Bibete Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Guangzhou Bibete Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Guangzhou Bibete Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Guangzhou Bibete Pharmaceutical ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Guangzhou Bibete Pharmaceutical FAQs
-
When was Guangzhou Bibete Pharmaceutical founded?
Guangzhou Bibete Pharmaceutical was founded in 2012.
-
Where is Guangzhou Bibete Pharmaceutical headquartered?
Guangzhou Bibete Pharmaceutical is headquartered in Guangzhou, China.
-
What is the size of Guangzhou Bibete Pharmaceutical?
Guangzhou Bibete Pharmaceutical has 160 total employees.
-
What industry is Guangzhou Bibete Pharmaceutical in?
Guangzhou Bibete Pharmaceutical’s primary industry is Drug Discovery.
-
Is Guangzhou Bibete Pharmaceutical a private or public company?
Guangzhou Bibete Pharmaceutical is a Public company.
-
What is Guangzhou Bibete Pharmaceutical’s stock symbol?
The ticker symbol for Guangzhou Bibete Pharmaceutical is 688759.
-
What is the current stock price of Guangzhou Bibete Pharmaceutical?
As of 13-Nov-2026 the stock price of Guangzhou Bibete Pharmaceutical is $2.43.
-
What is the current market cap of Guangzhou Bibete Pharmaceutical?
The current market capitalization of Guangzhou Bibete Pharmaceutical is $1.09B.
-
What is Guangzhou Bibete Pharmaceutical’s annual earnings per share (EPS)?
Guangzhou Bibete Pharmaceutical’s EPS for 12 months was -$0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
